| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794642 | Ophthalmology Retina | 2018 | 4 Pages |
Abstract
The increase in treatment interval for both intravitreal bevacizumab and dexamethasone implants over time has implications when informing patients about potential treatment burden for DME, planning intravitreal injections services, and designing future clinical trials. For drugs with a disease-modifying effect, fixed-interval dosing may not be required beyond an initial loading phase.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Hemal MA, FRCOphth, Samantha PhD, FRANZCO, Vuong PhD, Lyndell L. DMedSci, FRANZCO, Mark C. PhD, FRANZCO,